Latest News and Press Releases
Want to stay updated on the latest news?
-
Achilles Therapeutics appoints Carsten Boess to the Board of Directors Stevenage, UK 7 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell...
-
Achilles Therapeutics appoints Carsten Boess to the Board of Directors Stevenage, UK 7 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell...
-
Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officer - Professor Quezada is an internationally recognized leader in the field of cancer immunology and a founder of the...
-
Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officer - Professor Quezada is an internationally recognized leader in the field of cancer immunology and a founder of the...
-
Achilles Therapeutics Appoints Beverley Carr as Chief Business OfficerBrings 20+ years of business development experience Formerly VP, Business Development for the Immuno-inflammation Therapy Area at...
-
Achilles Therapeutics Appoints Beverley Carr as Chief Business OfficerBrings 20+ years of business development experience Formerly VP, Business Development for the Immuno-inflammation Therapy Area at...
-
Achilles Therapeutics raises £100 million in oversubscribed Series B financing - Leading international syndicate led by RA Capital and cornerstoned by founding investor Syncona- Confirms depth of...
-
Achilles Therapeutics raises £100 million in oversubscribed Series B financing - Leading international syndicate led by RA Capital and cornerstoned by founding investor Syncona- Confirms depth of...
-
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK 13 February...
-
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK 13 February...